163 related articles for article (PubMed ID: 37896207)
1. Anticancer Peptides Derived from Aldolase A and Induced Tumor-Suppressing Cells Inhibit Pancreatic Ductal Adenocarcinoma Cells.
Cui C; Huo Q; Xiong X; Li K; Fishel ML; Li B; Yokota H
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896207
[TBL] [Abstract][Full Text] [Related]
2. Anticancer peptides from induced tumor-suppressing cells for inhibiting osteosarcoma cells.
Cui CP; Huo QJ; Xiong X; Li KX; Ma P; Qiang GF; Pandya PH; Saadatzadeh MR; Bijangi Vishehsaraei K; Kacena MA; Aryal UK; Pollok KE; Li BY; Yokota H
Am J Cancer Res; 2023; 13(9):4057-4072. PubMed ID: 37818062
[TBL] [Abstract][Full Text] [Related]
3. Enhancing anti-tumor potential: low-intensity vibration suppresses osteosarcoma progression and augments MSCs' tumor-suppressive abilities.
Xiong X; Huo Q; Li K; Cui C; Chang C; Park C; Ku B; Hong CS; Lim H; Pandya PH; Saadatzadeh MR; Bijangi-Vishehsaraei K; Lin CC; Kacena MA; Pollok KE; Chen A; Liu J; Thompson WR; Li XL; Li BY; Yokota H
Theranostics; 2024; 14(4):1430-1449. PubMed ID: 38389836
[No Abstract] [Full Text] [Related]
4. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma.
Li K; Huo Q; Minami K; Tamari K; Ogawa K; Na S; Fishel ML; Li BY; Yokota H
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894284
[TBL] [Abstract][Full Text] [Related]
6. Aldolase A promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma.
Saito Y; Takasawa A; Takasawa K; Aoyama T; Akimoto T; Ota M; Magara K; Murata M; Hirohashi Y; Hasegawa T; Sawada N; Saito T; Osanai M
Cancer Sci; 2020 Aug; 111(8):3071-3081. PubMed ID: 32530543
[TBL] [Abstract][Full Text] [Related]
7. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
8. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
9. The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs).
Li K; Huo Q; Li BY; Yokota H
Proteomes; 2023 Jan; 11(1):. PubMed ID: 36810561
[TBL] [Abstract][Full Text] [Related]
10. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells.
Chen H; Ye Z; Xu X; Qin Y; Song C; Fan G; Hu H; Hu Y; Yu X; Liu W; Ji S; Xu W
Cancer Cell Int; 2021 Sep; 21(1):514. PubMed ID: 34565365
[TBL] [Abstract][Full Text] [Related]
11. Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes.
Li K; Sun X; Li H; Ma H; Zhou M; Minami K; Tamari K; Ogawa K; Pandya PH; Saadatzadeh MR; Kacena MA; Pollok KE; Li BY; Yokota H
Genes Dis; 2023 Jul; 10(4):1641-1656. PubMed ID: 37397541
[TBL] [Abstract][Full Text] [Related]
12. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer.
Ji S; Zhang B; Liu J; Qin Y; Liang C; Shi S; Jin K; Liang D; Xu W; Xu H; Wang W; Wu C; Liu L; Liu C; Xu J; Ni Q; Yu X
Cancer Lett; 2016 Apr; 374(1):127-135. PubMed ID: 26854714
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition.
Xiong C; Zhu Y; Xue M; Jiang Y; Zhong Y; Jiang L; Shi M; Chen H
Aging (Albany NY); 2021 Jan; 13(3):3386-3404. PubMed ID: 33428605
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins.
Li K; Huo Q; Dimmitt NH; Qu G; Bao J; Pandya PH; Saadatzadeh MR; Bijangi-Vishehsaraei K; Kacena MA; Pollok KE; Lin CC; Li BY; Yokota H
Elife; 2023 Mar; 12():. PubMed ID: 36943734
[TBL] [Abstract][Full Text] [Related]
15. Three unconventional maxims in the natural selection of cancer cells: Generation of induced tumor-suppressing cells (iTSCs).
Li K; Huo Q; Li BY; Yokota H
Int J Biol Sci; 2023; 19(5):1403-1412. PubMed ID: 37056934
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.
Kim YJ; Jung K; Baek DS; Hong SS; Kim YS
Oncogene; 2017 May; 36(18):2543-2552. PubMed ID: 27797376
[TBL] [Abstract][Full Text] [Related]
17. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
[TBL] [Abstract][Full Text] [Related]
18. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
19. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
20. CCR4
Sharma V; Sachdeva N; Gupta V; Nada R; Jacob J; Sahni D; Aggarwal A
Immunobiology; 2022 May; 227(3):152210. PubMed ID: 35358941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
